Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial
Lorenzo Falchi, Fritz Offner, Sven de Vos, Joshua Brody et autres
0 citationsBlood
Kim Linton
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
353Publications signalées
5904Citations signalées
4Affiliations récentes
Institutions déclarées
Domaines associés
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchCAR-T cell therapy researchCancer Immunotherapy and BiomarkersCNS Lymphoma Diagnosis and Treatment
Publications récentes
IBCL-1332: Phase 3 Results From the EPCORE FL-1 Trial of Epcoritamab With Lenalidomide and Rituximab vs Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma
Bradley D. Hunter, Lorenzo Falchi, Marcel Nijland, Huiqiang Huang et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
POSTER: IBCL-740: Anchored Matching-Adjusted Indirect Comparison of Epcoritamab, Lenalidomide, and Rituximab vs Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular Lymphoma: EPCORE FL-1 vs inMIND
Kim Linton, Moshe Levy, Dai Maruyama, Abel Costa et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
ORAL ABSTRACT: IBCL-1332: Phase 3 Results From the EPCORE FL-1 Trial of Epcoritamab (E) With Lenalidomide and Rituximab (R2) Versus R2 for Relapsed or Refractory Follicular Lymphoma (R/R FL)
Bradley D. Hunter, Lorenzo Falchi, Marcel Nijland, Huiqiang Huang et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
POSTER: IBCL-1332: Phase 3 Results From the EPCORE FL-1 Trial of Epcoritamab With Lenalidomide and Rituximab vs Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma
Bradley D. Hunter, Lorenzo Falchi, Marcel Nijland, Huiqiang Huang et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
IBCL-740: Anchored Matching-Adjusted Indirect Comparison of Epcoritamab, Lenalidomide, and Rituximab vs Tafasitamab, Lenalidomide, and Rituximab in Relapsed/Refractory Follicular Lymphoma: EPCORE FL-1 vs inMIND
Kim Linton, Moshe Levy, Dai Maruyama, Abel Costa et autres
0 citationsClinical Lymphoma Myeloma & Leukemia
MRD-negativity by PBMCs and ctDNA confirms deep and durable responses following epcoritamab monotherapy in R/R FL
Işıl Altıntaş, Christopher Morehouse, Elena Favaro, Ali Rana et autres
0 citationsBlood Advances
SWATH-MS for discovery of early biomarkers of drug-induced cardiotoxicity using an animal doxorubicin model
Rohan Shotton, A. Campbell, Ivona Baričević-Jones, Rachel Reed et autres
0 citationsCardio-Oncology
Treatment-related outcomes and patterns of relapse in secondary CNS involvement by large B-cell lymphoma
Juan Pablo Alderuccio, Diva Baggio, Sunwoo Han, Paola Ghione et autres
5 citationsBlood
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial
Lorenzo Falchi, Marcel Nijland, Huiqiang Huang, Kim Linton et autres
25 citationsThe Lancet
Data from CD27 Agonist Antibodies Mediate Clinical Responses through Intratumoral Stimulation in B-cell Malignancies: Multicenter RiVa Trial
Lara E. Buermann, Louise Stanton, Matthew Rose‐Zerilli, Kerensa Thorne et autres
0 citations
Supplementary Figure S10 from CD27 Agonist Antibodies Mediate Clinical Responses through Intratumoral Stimulation in B-cell Malignancies: Multicenter RiVa Trial
Lara E. Buermann, Louise Stanton, Matthew Rose‐Zerilli, Kerensa Thorne et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.